BioNTech SE (BNTX) Gets a Hold Rating from Goldman Sachs

Goldman Sachs analyst Chris Shibutani maintained a Hold rating on BioNTech SE (BNTXResearch Report) today and set a price target of $206.00. The company’s shares closed last Monday at $163.22, close to its 52-week low of $121.32.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.1% and a 47.4% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Arcutis Biotherapeutics, and Revolution Medicines.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $238.40 average price target, representing a 43.3% upside. In a report issued on May 9, Jefferies also maintained a Hold rating on the stock with a $230.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $464.00 and a one-year low of $121.32. Currently, BioNTech SE has an average volume of 1.59M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed